Kyverna Phase 2 miv-cel data shows 100% response rate at 24 weeks in gMG; durable to 52 weeks

Kyverna Therapeutics, Inc.

100% of 7 patients achieved ≥3-point reduction in MG-ADL and QMG (co-primary endpoints) at 24 weeks; mean reductions -8.5 and -11.3 points.
57% of patients achieved minimal symptom expression (MG-ADL 0 or 1) at last follow-up; responses deepened over time.
100% were free of nonsteroidal immunosuppressants, high-dose steroids, and FcRn/complement inhibitors through Week 24.
No high-grade CRS or ICANS; two transient grade 3/4 neutropenia events resolved; safety supports outpatient administration.
Median follow-up 10.2 months (range 3.3–16.0); company enrolling Phase 3 registrational trial across 14 sites.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.